Mixed Titer Performance Panel Accurately Tests for Dengue Virus

Panel members include samples from individuals with recent and past infection by all four dengue viruses (DENV-1 through DENV-4).

The Anti-Dengue Mixed Titer Performance Panel produced by SeraCare Life Sciences, Inc. (Milford, MA, USA) is available for purchase immediately worldwide. SeraCare's portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking, and contract research services.

Dengue fever is caused by one of four different but related viruses. It is spread by the bite of mosquitoes, most commonly the mosquito Aedes aegypti, which is found in tropic and subtropic regions. This includes parts of the Indonesian archipelago into northeastern Australia, South and Central America, Southeast Asia, Sub-Saharan Africa, and some parts of the Caribbean. Dengue fever is being seen more often in world travelers.

“Forty percent of the world’s population lives in areas at risk for dengue transmission,” said Chris Long, associate product manager at SeraCare Life Sciences. “Continued increases in global travel and immigration raise the risk of dengue virus transmission worldwide, well beyond the countries in which it is endemic. The new SeraCare Anti-Dengue Performance Panel responds to the rising world health issue and the corresponding need for assays that are well-challenged for accuracy and sensitivity.”

SeraCare panels are assembled from highly characterized natural patient samples. They are vital for assay development and regulatory compliance and provide a common reference for assay comparison and troubleshooting of existing assays.

Related Links:
SeraCare Life Sciences